145 related articles for article (PubMed ID: 3342412)
1. Effect of tetrahydrouridine on the clinical pharmacology of 1-beta-D-arabinofuranosylcytosine when both drugs are coinfused over three hours.
Kreis W; Chan K; Budman DR; Schulman P; Allen S; Weiselberg L; Lichtman S; Henderson V; Freeman J; Deere M
Cancer Res; 1988 Mar; 48(5):1337-42. PubMed ID: 3342412
[TBL] [Abstract][Full Text] [Related]
2. Pharmacology of combination chemotherapy of cytosine arabinoside (ara-C) and uracil arabinoside (ara-U) or tetrahydrouridine (THU) against murine leukemia L1210/0 in tumor-bearing mice.
Avramis VI; Powell W
Cancer Invest; 1987; 5(4):293-9. PubMed ID: 3664332
[TBL] [Abstract][Full Text] [Related]
3. Influence of tetrahydrouridine on the pharmacokinetics of intrathecally administered 1-beta-D-arabinofuranosylcytosine.
Riccardi R; Chabner B; Glaubiger DL; Wood J; Poplack DG
Cancer Res; 1982 May; 42(5):1736-9. PubMed ID: 6896013
[TBL] [Abstract][Full Text] [Related]
4. Therapy of refractory/relapsed acute leukemia with cytosine arabinoside plus tetrahydrouridine (an inhibitor of cytidine deaminase)--a pilot study.
Kreis W; Budman DR; Chan K; Allen SL; Schulman P; Lichtman S; Weiselberg L; Schuster M; Freeman J; Akerman S
Leukemia; 1991 Nov; 5(11):991-8. PubMed ID: 1961042
[TBL] [Abstract][Full Text] [Related]
5. Combinations of tetrahydrouridine and cytosine arabinoside in mouse tumors.
Kreis W; Hession C; Soricelli A; Scully K
Cancer Treat Rep; 1977 Oct; 61(7):1355-64. PubMed ID: 589601
[TBL] [Abstract][Full Text] [Related]
6. Tetrahydrouridine: Physiologic disposition and effect upon deamination of cytosine arabinoside in man.
Kreis W; Woodcock TM; Gordon CS; Krakoff IH
Cancer Treat Rep; 1977 Oct; 61(7):1347-53. PubMed ID: 589600
[TBL] [Abstract][Full Text] [Related]
7. Saturation of 1-beta-D-arabinofuranosylcytosine 5'-triphosphate accumulation in leukemia cells during high-dose 1-beta-D-arabinofuranosylcytosine therapy.
Plunkett W; Liliemark JO; Adams TM; Nowak B; Estey E; Kantarjian H; Keating MJ
Cancer Res; 1987 Jun; 47(11):3005-11. PubMed ID: 3471322
[TBL] [Abstract][Full Text] [Related]
8. Pharmacology studies of 1-beta-D-arabinofuranosylcytosine in pediatric patients with leukemia and lymphoma after a biochemically optimal regimen of loading bolus plus continuous infusion of the drug.
Avramis VI; Weinberg KI; Sato JK; Lenarsky C; Willoughby ML; Coates TD; Ozkaynak MF; Parkman R
Cancer Res; 1989 Jan; 49(1):241-7. PubMed ID: 2908850
[TBL] [Abstract][Full Text] [Related]
9. Effect of tetrahydrouridine on the action of 1-beta-D-arabinofuranosylcytosine in synchronized cultures of normal rat kidney cells.
Wan CW; Mak TW
Cancer Res; 1979 Oct; 39(10):3981-5. PubMed ID: 476637
[TBL] [Abstract][Full Text] [Related]
10. Phase I evaluation of tetrahydrouridine combined with cytosine arabinoside.
Wong PP; Currie VE; Mackey RW; Krakoff IH; Tan CT; Burchenal JH; Young CW
Cancer Treat Rep; 1979 Aug; 63(8):1245-9. PubMed ID: 383291
[TBL] [Abstract][Full Text] [Related]
11. Biochemical pharmacology of high dose 1-beta-D-arabinofuranosylcytosine in childhood acute leukemia.
Avramis VI; Biener R; Krailo M; Finklestein J; Ettinger L; Willoughby M; Siegel SE; Holcenberg JS
Cancer Res; 1987 Dec; 47(24 Pt 1):6786-92. PubMed ID: 3479250
[TBL] [Abstract][Full Text] [Related]
12. Clinical pharmacology of 1-beta-D-arabinofuranosylcytosine-5'-stearylphosphate, an orally administered long-acting derivative of low-dose 1-beta-D-arabinofuranosylcytosine.
Ueda T; Kamiya K; Urasaki Y; Wataya S; Kawai Y; Tsutani H; Sugiyama M; Nakamura T
Cancer Res; 1994 Jan; 54(1):109-13. PubMed ID: 8261429
[TBL] [Abstract][Full Text] [Related]
13. Relationship of 1-beta-D-arabinofuranosylcytosine in plasma to 1-beta-D-arabinofuranosylcytosine 5'-triphosphate levels in leukemic cells during treatment with high-dose 1-beta-D-arabinofuranosylcytosine.
Liliemark JO; Plunkett W; Dixon DO
Cancer Res; 1985 Nov; 45(11 Pt 2):5952-7. PubMed ID: 4053067
[TBL] [Abstract][Full Text] [Related]
14. Plasma and cerebrospinal fluid pharmacokinetics of 1-beta-D-arabinofuranosylcytosine and 1-beta-D-arabinofuranosyluracil following the repeated intravenous administration of high- and intermediate-dose 1-beta-D-arabinofuranosylcytosine.
Damon LE; Plunkett W; Linker CA
Cancer Res; 1991 Aug; 51(16):4141-5. PubMed ID: 1868435
[TBL] [Abstract][Full Text] [Related]
15. Minimum dose of fludarabine for the maximal modulation of 1-beta-D-arabinofuranosylcytosine triphosphate in human leukemia blasts during therapy.
Gandhi V; Estey E; Du M; Keating MJ; Plunkett W
Clin Cancer Res; 1997 Sep; 3(9):1539-45. PubMed ID: 9815841
[TBL] [Abstract][Full Text] [Related]
16. Modulation of the metabolism and pharmacokinetics of 1-beta-D-arabinofuranosylcytosine by 1-beta-D-arabinofuranosyluracil in leukemic mice.
Chandrasekaran B; Capizzi RL; Kute TE; Morgan T; Dimling J
Cancer Res; 1989 Jun; 49(12):3259-66. PubMed ID: 2720678
[TBL] [Abstract][Full Text] [Related]
17. Modulation of the cellular metabolism of cytarabine and fludarabine by granulocyte-colony-stimulating factor during therapy of acute myelogenous leukemia.
Gandhi V; Estey E; Du M; Nowak B; Keating MJ; Plunkett W
Clin Cancer Res; 1995 Feb; 1(2):169-78. PubMed ID: 9815970
[TBL] [Abstract][Full Text] [Related]
18. Pharmacology and toxicology of a seven-day infusion of 1-beta-D-arabinofuranosylcytosine plus uridine in dogs.
Perlow L; Ohnuma T; Andrejczuk A; Shafir M; Strauchen J; Holland JF
Cancer Res; 1985 Jun; 45(6):2572-7. PubMed ID: 3986795
[TBL] [Abstract][Full Text] [Related]
19. High-dose idarubicin in combination with Ara-C in patients with relapsed or refractory acute lymphoblastic leukemia: a pharmacokinetic and clinical study.
Tedeschi A; Montillo M; Strocchi E; Cafro AM; Tresoldi E; Intropido L; Nichelatti M; Marbello L; Baratè C; Camaggi CM; Morra E
Cancer Chemother Pharmacol; 2007 May; 59(6):771-9. PubMed ID: 17256136
[TBL] [Abstract][Full Text] [Related]
20. Effect of tetrahydrouridine on metabolism and transport of 1-beta-D-arabinofuranosylcytosine in human cells.
Riva C; Barra Y; Carcassonne Y; Cano JP; Rustum Y
Chemotherapy; 1992; 38(5):358-66. PubMed ID: 1286578
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
